Highlights GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:30:00 2026-01-21 EST			5-day change	1st Jan Change
1,781.00 ^GBX	-0.81%		-5.24%	-2.33%

07:23am	GSK : UBS remains Neutral	ZD
06:38am	RTW Biotech welcomes GSK deal to buy RAPT Therapeutics	AN

Highlights

06:38am	RTW Biotech welcomes GSK deal to buy RAPT Therapeutics	AN
10:13pm	PRESS DIGEST-Financial Times - Jan 21	RE
01-20	Top Midday Gainers	MT
01-20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
01-20	Sector Update: Health Care Stocks Decline Premarket Tuesday	MT
01-20	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
01-20	Top Premarket Gainers	MT
01-20	RAPT Therapeutics Shares Jump Following Acquisition by GSK	DJ
01-20	GSK's Tesaro Licenses Alteogen Enzyme Technology	MT
01-20	Deals of the day-Mergers and acquisitions	RE
01-20	GSK to Bolster Immunology Pipeline With $2.2 Billion Rapt Therapeutics Acquisition	MT
01-20	GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update	DJ
01-20	GSK plc entered a definitive agreement to acquire RAPT Therapeutics, Inc. for $1.6 billion.	CI
01-20	Shionogi & Co Invests $2.13 Billion to Replace Pfizer as ViiV Healthcare Shareholder	MT
01-20	Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake	RE
01-20	GSK to Buy RAPT Therapeutics in $2.2 Billion Deal; Shares Up Pre-Bell	MT
01-20	GSK boosts pipeline with USD2.2 billion purchase of RAPT Therapeutics	AN
01-20	GSK Partner Shionogi to Acquire Pfizer's Stake in HIV-Focused ViiV Healthcare for $2.13 Billion	MT
01-20	Alteogen Inc. Announces Exclusive License Agreement with Tesaro, Inc. for the Development of Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme Technology	CI
01-20	GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments	DJ
01-20	GSK, Shionogi Finalize Deal for Pfizer's Exit from ViiV Healthcare	MT
01-20	GSK to Buy US-based Rapt Therapeutics in $2.2 Billion Deal	MT
01-20	GSK to acquire RAPT Therapeutics for $2.2 bln	RE
01-20	GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug	RE
01-20	UK Stocks-Factors to watch on January 20	RE